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Exenatide Sensitizes Insulin-Mediated Whole-Body
Glucose Disposal and Promotes Uptake of Exogenous
Glucose by the Liver
Dan Zheng, Viorica Ionut, Vahe Mooradian, Darko Stefanovski, and Richard N. Bergman
OBJECTIVE—Recent progress suggests that exenatide, a mi-
metic of glucagon-like peptide-1 (GLP-1), might lower glycemia
independent of increased -cell response or reduced gastrointes-
tinal motility. We aimed to investigate whether exenatide stimu-
lates glucose turnover directly in insulin-responsive tissues
dependent or independent of insulinemia.
RESEARCH DESIGN AND METHODS—An intraportal glu-
cose infusion clamp was used in dogs to measure glucose
turnover to encompass potent activation of the putative
glucose/GLP-1 sensor in the porto-hepatic circulation with
exenatide. The modiﬁed glucose clamp was performed in the
presence of postprandial hyperinsulinemia and hyperglycemia
with exenatide (20 g) or saline injected at 0 min. Further-
more, the role of hyperglycemia versus hyperinsulinemia in
exenatide-mediated glucose disposal was studied.
RESULTS—With hyperinsulinemia and hyperglycemia, ex-
enatide produced a signiﬁcant increase in total glucose turn-
over by 30%, as indicated by portal glucose infusion rate
(saline 15.9  1.6 vs. exenatide 20.4  2.1 mg  kg
1  min
1,
P  0.001), resulting from increased whole-body glucose
disposal (Rd, 20%) and increased net hepatic uptake of
exogenous glucose (80%). Reducing systemic hyperglycemia
to euglycemia, exenatide still increased total glucose turnover
by 20% (saline 13.2  1.9 vs. exenatide 15.6  2.1 mg  kg
1
 min
1, P  0.05) in the presence of hyperinsulinemia,
accompanied by smaller increments in Rd (12%) and net
hepatic uptake of exogenous glucose (45%). In contrast,
reducing hyperinsulinemia to basal levels, exenatide-in-
creased total glucose turnover was completely abolished
despite hyperglycemia (saline 2.9  0.6 vs. exenatide 2.3  0.3
mg  kg
1  min
1, P  0.29).
CONCLUSIONS—Exenatide directly stimulates glucose turn-
over by enhancing insulin-mediated whole-body glucose disposal
and increasing hepatic uptake of exogenous glucose, contribut-
ing to its overall action to lower postprandial glucose excursions.
Diabetes 58:352–359, 2009
E
xenatide is the synthetic form of exendin-4 and
a long-acting mimetic of the incretin hormone
glucagon-like peptide-1 (GLP-1) (1). Originally
isolated from salivary secretions of the lizard
Gila monster, exendin-4 shows a 53% amino acid sequence
identity to GLP-1 (2) and shares many actions with GLP-1
via pancreatic GLP-1 receptor (3). Exenatide stimulates
glucose-dependent insulin response (4–6), suppresses glu-
cagon secretion (5), and inhibits gastrointestinal motility
(7). Exenatide has also been implicated in regulating food
intake (8) and -cell proliferation (9). Exenatide is resis-
tant to digestion by dipeptidyl peptidase-IV and thus has a
longer plasma half-life than GLP-1 (10).
Exenatide is currently used in the treatment of type 2
diabetes because of its effect to lower glycemia and
improve glycemic control through multiple mechanisms as
mentioned above. Exenatide (13 weeks) in diabetic db/db
mice led to 50% lower glycosylated hemoglobin (A1C) than
in nontreated animals (4). Type 2 diabetic patients who
had not attained A1C goals 8% with sulfonylureas and/or
metformin achieved a 0.9% reduction with exenatide (4
weeks) (11).
However, it appears that exenatide-improved glycemic
control cannot be completely explained by its currently
established actions. In particular, exenatide may have a
direct effect on insulin-responsive tissues, although this
latter effect is still under debate. In obese Zucker rats,
exenatide (6 weeks) dramatically enhanced insulin sensi-
tivity while preventing the progressive increase in A1C and
fasting insulin (12). When compared with pair-fed animals
with matching A1C, fasting glucose, insulin, and lipids,
insulin sensitivity was still 64% higher with exenatide. In
another study, exenatide administered with meals to type
2 diabetic patients resulted in reduced glucose excursions
facing signiﬁcantly lower postprandial insulin levels, not
higher, as expected based on the insulinotropic effect of
exenatide (5). The reduced postprandial glucose excur-
sion has been attributed to exenatide inhibition of gastric
emptying and/or glucagon secretion (5,7). However, by
simulating intraportal rate of glucose appearance (Ra)i n
portal vein after meal with or without exenatide (thus
bypassing its gastrointestinal effect), we have shown that
exenatide lowered glycemia in the presence of similar
insulin and glucagon levels (13). Although some studies
have failed to show acute effects of exenatide on insulin
action (14,15), our previous result suggests a potential
exenatide effect to increase insulin sensitivity. The goal of
our current study was to investigate whether exenatide
directly stimulates glucose turnover dependent or inde-
pendent of insulinemia in insulin-responsive tissues.
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Experiments were conducted in male mongrel dogs (Harlan, Indianapolis, IN),
housed under controlled conditions and fed once daily (Labdiet; PMI Nutrition
International, Richmond IN). Animals were used for experiments only if they
were judged to be in good health as determined by body weight, food intake
and stools, temperature, hematocrit, and direct observation. All surgical and
experimental procedures were approved by USC Institutional Animal Care
and Use Committee.
Surgical procedures. At least 1 week before the ﬁrst experiments, chronic
catheters (Tygon, inner diameter  0.05 inch; Norton Plastics, Akron, OH)
were implanted under general anesthesia. One catheter was placed in jugular
vein (with the tip advanced into right atrium) and the other in portal vein
(4-cm upstream from porta hepatis). All catheters, ﬁlled with heparinized
saline (10 units/ml), were led subcutaneously to the back of the neck,
exteriorized, and secured in place.
Experimental design. Experiments were performed on animals in a con-
scious relaxed state. Animals were fasted for 14–16 h with free access to
water. For all experiments, animals were brought to the laboratory at 6:00
A.M. and placed into a Pavlov sling. Three types of experiments were
performed in paired experiments with subcutaneous injection of either
exenatide or saline to examine the effect of exenatide on glucose turnover. In
all studies, we used a novel glucose clamp technique, the intraportal glucose
infusion–glucose clamp. Unlike the classical clamp where exogenous
glucose is given systemically, in these experiments, we infused exogenous
glucose directly into portal vein to maintain the desired systemic glycemia.
Previous evidence has suggested the presence of glucose sensors in the
porto-hepatic circulation that may interact with GLP-1 to affect glucose
clearance (16–22). Intraportal glucose infusion was used to stimulate any
extant portal/hepatic sensors, as would happen during postprandial nutri-
tional entry of carbohydrate into the systemic circulation. The intraportal
glucose infusion–glucose clamp was performed under the following condi-
tions: study 1, in the presence of hyperinsulinemia and hyperglycemia; study
2, in the presence of hyperinsulinemia but systemic euglycemia; and study 3,
in the presence of hyperglycemia but basal insulin levels.
Study 1: Effect of exenatide on glucose turnover in the presence of
postprandial hyperinsulinemia and hyperglycemia. Paired experi-
ments with or without a single subcutaneous injection of exenatide were
performed in nine animals (eight with tracer infusions), 28.8  0.5 kg body
wt. The modiﬁed glucose clamp was composed of two periods: a 2-h
equilibrium period (120 to 0 min), followed by injection of saline or
exenatide, and a 4-h experimental period (0–240 min; Fig. 1A). At 120
min, immediately after a systemic injection of 25-Ci bolus of [3-
3H]D-
glucose (“tracer”; DuPont-NEN, Boston, MA), a continuous infusion of
tracer at 0.25 Ci/min was initiated via a peripheral venous catheter.
Ninety minutes later, blood samples for the basal period were taken every
10 min from 30 to 0 min. At 0 min, peripheral infusions of somatostatin
(Bachem, Torrance, CA), at 1 g  kg
1  min
1, and porcine insulin (Eli
Lilly, Indianapolis, IN), at 0.75 mU  kg
1  min
1, were initiated to obtain
systemic hyperinsulinemia of 250 pmol/l. An intraportal infusion of
porcine glucagon (Sigma, St. Louis, MO), at 0.65 ng  kg
1  min
1, was
simultaneously started to maintain plasma glucagon at basal levels. At 0
min, a single subcutaneous injection of either exenatide (20 g Byetta;
Amylin, San Diego, CA) or saline of equal volume was administered in
paired experiments. During the experimental phase (0–240 min), blood
samples were taken from another peripheral venous catheter every 10 min;
plasma glucose were measured immediately. Exogenous glucose (50%
dextrose, 454.5 mg/ml; B Braun, Irvine, CA) was given via the portal vein
catheter at variable rates to maintain systemic glucose at 150 mg/dl. An
additional tracer infusion was given at variable rates via the jugular vein
catheter to minimize ﬂuctuations in systemic plasma speciﬁc activity; the
ratio between the rate of the additional systemic tracer infusion and that
of intraportal glucose infusion was kept at 1.8 Ci/g. The average of the
four samples taken from 150–180 min was deﬁned as the clamp steady
state when plasma glucose, insulin, and exogenous glucose infusion rate
were least variable.
Study 2: Effect of exenatide on glucose turnover in the presence of
hyperinsulinemia but systemic euglycemia. Paired experiments with or
without a single subcutaneous injection of exenatide were conducted in eight
animals (six with tracer infusions), 28.2  0.7 kg body wt. The modiﬁed
glucose clamp was used to measure glucose turnover as discussed above,
except that intraportal glucose infusion was given to maintain systemic
glucose at basal levels (Fig. 1A).
Study 3: Effect of exenatide on glucose turnover in the presence of
hyperglycemia but basal insulin levels. Paired experiments with or with-
out a single subcutaneous injection of exenatide were carried out in six
animals (six with tracer infusions), 29.5  0.8 kg body wt. The modiﬁed
glucose clamp was used to measure glucose turnover as discussed in study 1,
except that plasma insulin was maintained at basal levels by a low infusion
rate of 0.15 mU  kg
1  min
1 while systemic glucose was raised to 150 mg/dl
(Fig. 1A).
Blood sampling. Samples for the determination of glucose, free fatty acids
(FFAs), insulin, C-peptide, glucagon, and tracer were collected as previously
described (16,23). All samples were immediately centrifuged, and plasma was
separated and stored at 80°C until analysis. To prevent triglyceride break-
down, FFAs samples were kept on ice and either immediately assayed or kept
at 80°C for a limited time before assay, as previously described (16).
Assays. Glucose was measured with a YSI 2700 autoanalyzer (Yellow Springs
Instruments, Yellow Springs, OH). Insulin was measured using a human
insulin ELISA kit (Linco/Millipore, Billerica, MA) adapted for dog plasma (24).
C-peptide and glucagon were measured using radioimmunoassay kits (Linco/
Millipore). FFAs were determined using an enzymatic colorimetric assay
(NEFA C; Wako Pure Chemical Industries, Richmond, VA). Samples for
[3-
3H]-D-glucose were deproteinized, dried, resuspended in scintillation ﬂuid
(Readysafe; Beckman, Fullerton, CA), and then read in a -scintillation
counter.
Calculations. Two metabolic parameters can be calculated from the
intraportal glucose infusion clamp: whole-body glucose disposal and a
parameter we named “net hepatic glucose addition” (NHGA). The time
course of whole-body glucose disposal [rate of glucose disappearance
(Rd)] was calculated using Steele’s equation with a labeled glucose infusion
(25) after data smoothing using OOPSEG (26). Because exogenous glucose
was infused directly into portal vein, a fraction of intraportally given
glucose would be taken up by the liver without entering the systemic circula-
tion; referred to as 1st-pass hepatic glucose uptake (1st-pass HGU). Therefore, the
Ra equals portal glucose infusion (PoGinf) plus endogenous glucose production
(EGP) minus 1st-pass HGU (Eq. 1). The difference between EGP and 1st-pass
HGU, which is deﬁned as NHGA, is thus derived from the difference between Ra
Exenatide or Saline
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Basal Clamp  SS 
25 µCi + 0.25 µCi/min [3-3H]-D-Glucose
Peripheral 
Exogenous glucose @ variable rates
[3-3H]-D-Glucose @ variable rates
Somatostatin 1 µg/kg/min
Insulin infusion
Intraportal
Glucagon 0.65 ng/kg/min
Portal vein
Liver
Rest of 
Body
PoGinf
Liver uptake
(1st-pass HGU) Ra
Glucose label
Rd
EGP
Ra = PoGinf + EGP – 1stpass HGU
Ra - PoGinf = EGP – 1stpass HGU = NHGA
Ra = PoGinf + (EGP – 1STpass HGU) =  PoGinf + NHGA
A
B
FIG. 1. A: Intraportal glucose infusion clamp. Basal and clamp SS
indicate the steady state during the basal and clamp period, respec-
tively. Porcine insulin was infused at either 0.75 (studies 1 and 2) or
0.15 mU  kg
1  min
1 (study 3) to achieve postprandial hyperinsulin-
emia or maintain basal insulin levels. Exogenous glucose was given
into portal vein to achieve systemic hyperglycemia (studies 1 and 3) or
maintain systemic euglycemia (study 2). B: Calculation of NHGA.
Glucose label indicates the constant and the variable tracer infusions.
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similar to Rd.
Ra  PoGinf  EGP  1st-pass HGU (1)
Ra  PoGinf  EGP  1st-pass HGU  NHGA (2)
Ra  PoGinf  (EGP  1st-pass HGU)  PoGinf  NHGA (3)
In an intraportal glucose infusion–glucose clamp, NHGA, as the name
implies, reﬂects the net addition of glucose by the liver to portally infused
exogenous glucose (Eq. 3). During the basal period, PoGinf and 1st-pass HGU
both equal 0; thus, Ra  EGP  NHGA. During the experimental period, under
the inﬂuence of elevated insulin and/or glucose levels, EGP decreases while
1st-pass HGU increases. A positive NHGA indicates EGP	1st-pass HGU, i.e.,
there is a net addition of glucose by the liver to portally infused glucose and
thus systemic Ra	PoGinf. A negative NHGA indicates EGP1st-pass HGU,
i.e., there is a net uptake of glucose by the liver from portally infused glucose
and thus systemic RaPoGinf. Physiologically, the parameter NHGA (EGP 
1st-pass HGU) represents, in postprandial situations, the net effect of the liver
on Ra in the systemic circulation by changing EGP and 1st-pass HGU (Ra 
PoGinf  NHGA). It is noteworthy that NHGA is different from net hepatic
glucose balance (NHGB). The latter is calculated as the arteriovenous
difference of hepatic glucose input and output; NHGB  EGP  total HGU
(not just 1st-pass HGU).
Statistics. All experimental data are expressed as means  SE. Two-way
ANOVA was used to compare time course data with or without exenatide.
Paired Student’s t test was used to compare the basal or clamp steady-state
parameters between saline and exenatide treatments. Differences were con-
sidered statistically signiﬁcant at P  0.05.
RESULTS
Study 1: The effect of exenatide on glucose turnover
in the presence of postprandial hyperinsulinemia and
hyperglycemia. We ﬁrst studied the effect of exenatide on
glucose turnover in the presence of postprandial insulin
and glucose levels. The time courses of plasma insulin and
glucose were matched between the saline and exenatide
groups, with insulin raised to 225 pmol/l and glucose
raised to 150 mg/dl at the clamp steady state (Table 1).
The total glucose turnover, as indicated by portal glu-
cose infusion rate, was elevated with exenatide, increasing
30% at steady state (15.9  1.6 saline vs. 20.4  2.1
exenatide mg  kg
1  min
1, P  0.001; Fig. 2A). Increased
glucose turnover was a result of both increased whole-
body glucose disposal (Rd) and increased net hepatic
uptake of portal exogenous glucose. Rd was increased
by 20% (15.5  1.5 saline vs. 18.3  2.1 exenatide mg 
kg
1  min
1, P  0.05; Fig. 2B). NHGA was quickly
switched from net addition to net uptake (1st-pass), which
was increased by 80% with exenatide (1.2  0.2 saline vs.
2.2  0.3 exenatide mg  kg
1  min
1, P  0.05; Fig. 2C).
Endogenous insulin secretion was suppressed with so-
matostatin, as reﬂected by plasma C-peptide levels, which
were signiﬁcantly reduced at steady state in both groups.
Plasma glucagon was replaced near basal levels and
matched between groups. Plasma FFAs were quickly and
completely suppressed in both groups (Table 1).
Study 2: The effect of exenatide on glucose turnover
in the presence of hyperinsulinemia but systemic
euglycemia. To dissect the role of hyperglycemia in
exenatide-mediated glucose turnover, the effect of ex-
enatide on glucose turnover was examined in the presence
of hyperinsulinemia but systemic euglycemia (reduced
glycemia intraportally). The time courses of plasma insulin
and glucose were superimposable between the saline and
exenatide groups, with insulin raised to 245 pmol/l and
glucose clamped at basal (94 mg/dl) at the clamp steady
state (Table 2). At systemic euglycemia, total glucose
turnover was still increased with exenatide but to a lesser
degree, increasing 20% at steady state (13.2  1.9 saline
vs. 15.6  2.1 exenatide mg  kg
1  min
1, P  0.05; Fig.
3A). Accordingly, Rd was only increased by 12%, but the
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FIG. 2. Intraportal glucose infusion clamp in the presence of postpran-
dial hyperinsulinemia and hyperglycemia. Time course (left) and clamp
steady-state (right) data of intraportal glucose infusion rate (PoGinf)
(A), Rd (B), and NHGA (C) in the saline (SAL, E) and exenatide (EX,
F) groups. *P < 0.05, signiﬁcantly different from saline.
TABLE 1
Intraportal glucose infusion clamp in the presence of postprandial hyperinsulinemia and hyperglycemia: basal and clamp steady-state
parameters in the saline- and exenatide-treated groups
Basal Clamp steady state
Saline Exenatide Saline Exenatide
Glucose (mg/dl) 92.6  1.6 89.4  2.1* 150.2  2.8† 157.4  4.3†
Insulin (pmol/l) 41.3  4.5 45.8  4.0 231.5  10.5† 217.9  11.5*†
C-peptide (ng/ml) 0.24  0.06 0.25  0.06 0.06  0.06† 0.05  0.04†
Glucagon (ng/l) 42.5  4.2 50.8  6.4 33.3  3.2 33.5  3.9†
FFAs (mmol/l) 0.58  0.06 0.55  0.11 0.02  0.01† 0.03  0.03†
Data are means  SE. *P  0.05 signiﬁcantly different from the saline group. †P  0.05 signiﬁcantly different from basal in each group.
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2.4 exenatide mg  kg
1  min
1, P  0.05; Fig. 3B). The
increment in net hepatic uptake of portal exogenous
glucose was 45%, which was signiﬁcant over the entire
time course (1.1  0.1 saline vs. 1.6  0.5 exenatide
mg  kg
1  min
1, P  0.005 time course, whereas P  0.33
steady state; Fig. 3C). Again, no difference was found in
plasma C-peptide, glucagon, and FFAs between groups
(Table 2).
Study 3: The effect of exenatide on glucose turnover
in the presence of hyperglycemia but basal insulin
levels. To investigate whether hyperinsulinemia is re-
quired for the effect of exenatide on glucose disposal, the
effect of the compound was examined in the presence of
hyperglycemia but basal insulin levels. The time courses of
plasma insulin and glucose were matched between the
saline and exenatide groups, with insulin maintained at
basal levels (45 pmol/l) and systemic glucose elevated
to 150 mg/dl (Table 3). In sharp contrast to studies 1
and 2, in the absence of hyperinsulinemia, exenatide did
not cause an increase in total glucose turnover despite
elevated glycemia (2.9  0.6 saline vs. 2.3  0.3 ex-
enatide mg  kg
1  min
1 at steady state, P  0.29; Fig.
4A). Hence, without hyperinsulinemia, whole-body glu-
cose disposal did not differ between groups; a slight
increment from basal levels resulting from elevated
glycemia occurred similarly in both groups (4.1  0.5
saline vs. 4.0  0.3 exenatide mg  kg
1  min
1, P  0.77;
Fig. 4B). Without hyperinsulinemia, exenatide did not
induce net hepatic uptake of portally infused glucose
either; net addition was simply suppressed to 50% of
basal levels (1.3  0.1 saline vs. 1.4  0.2 exenatide mg 
kg
1  min
1, P  0.77; Fig. 4C). Again, no difference was
found in plasma C-peptide, glucagon, and FFAs proﬁles
between groups (Table 3).
In Fig. 5, we summarized clamp steady-state values of
Rd and NHGA versus their respective plasma insulin or
glucose levels from the three studies. In the absence of
elevated insulin levels (study 3), no difference was induced
by exenatide either in Rd or in NHGA despite the presence
of hyperglycemia (Rd, Fig. 5A; and NHGA, Fig. 5C). In
contrast, raising insulin to postprandial levels, a signiﬁcant
enhancement in whole-body glucose disposal with ex-
enatide occurred at similar systemic hyperglycemia (study
3 vs. study 1; Fig. 5A). At hyperinsulinemia, a greater net
hepatic uptake of portal exogenous glucose was also
induced with exenatide facing similar hepatic glucose load
(estimated by plasma glucose 
 hepatic ﬂow  portal
glucose infusion; study 3 vs. study 2; Fig. 5C). Hyperinsu-
linemia is a prerequisite for exenatide-mediated glucose
disposal, pointing to an insulin-sensitizing effect of ex-
enatide. In addition, at similar hyperinsulinemia, raising
systemic glycemia from basal levels to 150 mg/dl (study
2 vs. study 1), the increments in Rd (Fig. 5B) and in net
hepatic uptake of exogenous glucose (Fig. 5D) were
further increased. Hyperglycemia further enhanced ex-
enatide-mediated glucose disposal only in the presence of
elevated insulinemia, again indicating increased insulin
sensitivity with exenatide.
DISCUSSION
It has been shown that exenatide improves glycemic
control primarily by reducing postprandial hyperglycemia
(27). Multiple mechanisms have been implicated in this
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FIG. 3. Intraportal glucose infusion clamp in the presence of hyperin-
sulinemia but systemic euglycemia. Time course (left) and clamp
steady-state (right) data of intraportal glucose infusion rate (PoGinf)
(A), Rd (B), and NHGA (C) in the saline (SAL, E) and exenatide (EX,
F) groups. *P < 0.05, signiﬁcantly different from saline.
TABLE 2
Intraportal glucose infusion clamp in the presence of hyperinsulinemia but systemic euglycemia: basal and clamp steady-state
parameters in the saline- and exenatide-treated groups
Basal Clamp steady state
Saline Exenatide Saline Exenatide
Glucose (mg/dl) 93.1  1.9 93.0  1.5 91.2  2.9 96.2  2.5
Insulin (pmol/l) 39.5  5.5 47.7  4.0 246.3  11.7* 242.8  10.9*
C-peptide (ng/ml) 0.21  0.05 0.23  0.05 0.04  0.03* 0.06  0.03*
Glucagon (ng/l) 47.3  4.6 47.8  5.8 31.1  4.0* 30.1  5.2*
FFAs (mmol/l) 0.64  0.06 0.57  0.07 0.04  0.01* 0.03  0.01*
Data are means  SE. *P  0.05 signiﬁcantly different from basal in each group.
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the gastrointestinal tract, and the brain (3). The central
ﬁnding of the present study is that exenatide also directly
stimulates glucose turnover by enhancing insulin-medi-
ated whole-body glucose disposal and increasing uptake of
exogenous glucose by the liver, contributing to its overall
action to lower postprandial glucose excursion.
Currently, available information regarding the effect of
exenatide or GLP-1 on glucose turnover is not consistent
(14,28–30). Although the discrepancies may be explained
by different study designs or subjects used, one explana-
tion could be a GLP-1/glucose sensor in the porto-hepatic
region to mediate the glucose-lowering effect of exenatide
and GLP-1. The existence of such a GLP-1 sensing mech-
anism has been suggested by anatomical and functional
studies, showing GLP-1 receptors expressed on nerve
terminals in portal vein (21) and increased vagal discharge
rate by intraportal GLP-1 infusion (20). Moreover, concur-
rent portal hyperglycemia appears to be required for the
activation of GLP-1 sensor (16–19,22). We have shown that
intraportal GLP-1 does not lower systemic glucose unless
it is paired with intraportal (but not systemic) glucose
infusion (16). Therefore, we used the intraportal glucose
infusion clamp to measure exenatide-mediated glucose
turnover, which mimics the postprandial nutritional entry
into the systemic circulation, potentially stimulating the
putative portal sensor with exenatide. Although adminis-
tered subcutaneously, portal exenatide concentration
should increase effectively because of its longer plasma
half-life than GLP-1 (3). Exenatide was given at 20 g, a
recommended clinical daily dose. We have previously
conﬁrmed that this dose induces a signiﬁcant improve-
ment in glucose tolerance and is well tolerated in dogs
(13), so we expected it to provide important information
regarding the mechanism of action of exenatide. In the
future, dose-response studies can be done to determine
the relative importance of the different effects of this agent
to enhance glucose tolerance (delayed gastric emptying,
glucagon suppression, enhancement of insulin response,
and now, improved insulin action).
Using such a modiﬁed glucose clamp, we ﬁrst measured
a signiﬁcant increase in total glucose turnover with ex-
enatide in the presence of postprandial insulin and glucose
levels, as a result of increased whole-body glucose dis-
posal and increased net hepatic uptake of portal exoge-
nous glucose (study 1). This ﬁnding supports the concept
that exenatide directly stimulates glucose turnover. This
ﬁnding also raised the question of whether exenatide
might increase glucose disposal via potentiating insulin
action or enhancing glucose-mediated glucose disposal, or
independent of elevated insulinemia and glycemia. When
lowering systemic hyperglycemia to basal levels (study 2),
the increased glucose disposal was maintained, although
reduced, both in glucose utilization and in NHGA (net
uptake) in the presence of elevated insulinemia. In sharp
contrast, reducing insulinemia from postprandial to basal
levels (study 3), the increased glucose disposal was com-
pletely abolished both for glucose utilization and NHGA
despite elevated glycemia. Therefore, it appears that hy-
perinsulinemia is a prerequisite for exenatide-mediated
glucose disposal, suggesting an insulin-sensitizing effect of
exenatide. Hyperglycemia further enhances exenatide-me-
diated glucose disposal only in the presence of elevated
insulinemia, again supporting increased insulin action
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FIG. 4. Intraportal glucose infusion clamp in the presence of hypergly-
cemia but basal insulin levels. Time course (left) and clamp steady-
state (right) data of intraportal glucose infusion rate (PoGinf) (A), Rd
(B), and NHGA (C) in the saline (SAL, E) and exenatide (EX, F)
groups.
TABLE 3
Intraportal glucose infusion clamp in the presence of hyperglycemia but basal insulin levels: basal and clamp steady-state parameters
in the saline- and exenatide-treated groups
Basal Clamp steady state
Saline Exenatide Saline Exenatide
Glucose (mg/dl) 89.5  0.8 90.0  1.7 151.0  2.8* 153.4  4.3*
Insulin (pmol/l) 41.1  4.5 54.3  3.3† 44.4  1.8 42.2  2.7*
C-peptide (ng/ml) 0.20  0.03 0.19  0.05 0.01  0.01* 0.00  0.00*
Glucagon (ng/l) 45.3  7.3 50.8  8.9 38.1  6.3* 39.2  7.2*
FFAs (mmol/l) 0.44  0.05 0.43  0.07 0.23  0.04* 0.22  0.03*
Data are means  SE. *P  0.05 signiﬁcantly different from basal in each group. †P  0.05 signiﬁcantly different from the saline group.
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glycemia.
An enhancement of insulin sensitivity with exenatide
using the hyperinsulinemic-euglycemic clamp has been
reported in chronic studies performed in diabetic or
insulin-resistant animal models (12,28,31). But, concurrent
changes in food intake, body weight, and metabolic pa-
rameters can affect insulin sensitivity and make it difﬁcult
to differentiate the direct versus indirect effects of ex-
enatide on insulin action. In one study, food intake, body
weight, plasma glucose, insulin, and lipid levels were
matched in pair-fed animals (12). A 50% increase in
insulin sensitivity with exenatide was maintained, support-
ing the direct role of the peptide in insulin action. Enhanc-
ing insulin sensitivity by exenatide has also been
suggested by other studies in which the effect of exenatide
on postprandial glycemia was investigated (5,7,27). When
exenatide is administered with a meal, signiﬁcantly lower
plasma glucose occurs without a corresponding increase
in insulin secretion. Decreased gastric emptying and lower
plasma glucagon level partially explain the lowered glu-
cose excursion, although enhanced insulin sensitivity can-
not be ruled out as a contributing factor. By simulating
portal Ra in portal vein after meal with or without ex-
enatide (thus bypassing gastrointestinal tract), we have
shown that exenatide lowers systemic glucose levels in the
absence of corresponding changes in plasma insulin and
glucagon (13). Similar results have been found in studies
using GLP-1, which leads to lowered postprandial plasma
glucose accompanied by lowered insulin levels (32,33). In
one study, erythromycin was used to antagonize the effect
of GLP-1 on gastric emptying (32). With matching gastric
emptying between the GLP-1 plus erythromycin and the
control groups, plasma insulin rose similarly in both
groups after a meal. Yet, plasma glucose was still
partially lower than the control. These results suggest a
possible role of exenatide to enhance postprandial
insulin sensitivity.
In contrast to positive results, some studies failed to
reveal an acute effect of exenatide on insulin sensitivity
using the hyperinsulinemic-euglycemic clamp (14,15).
Several factors might explain the lack of an insulin-
sensitizing effect in these negative studies. First, in
these latter studies, intraportal glucose was not raised
signiﬁcantly, and thus, the putative portal GLP-1/glucose
sensor may have been left inactive. As we mentioned,
intraportal GLP-1 lowers systemic glucose only when
paired with intraportal but not systemic glucose infu-
sion (16,19). In addition, exendin 9–39 (GLP-1 receptor
antagonist) infused portally at a low rate attenuates the
glucose-lowering effect exenatide (17). It appears that
the putative GLP-1/glucose sensor might at least par-
tially mediate the glucose-lowering effect of GLP-1 and
exenatide. In chronic studies, exenatide was given twice
a day with meals for 6 weeks (12,28,31), continuously
producing the putative portal signals. Signiﬁcant
changes in insulin signaling pathways and/or glucose
transporting systems might occur (34), and thus, en-
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readily detected. Second, cortisol, known to induce
insulin resistance, increased with the treatment of ex-
endin-4 in these studies, which might offset possible
exenadin-4–increased insulin action (14). Instead, in the
present study, plasma cortisol levels were matched
between the saline control and exenatide groups (data
not shown).
An interesting aspect of the present study is the effect
of exenatide on hepatic glucose turnover. In the pres-
ence of hyperinsulinemia and hyperglycemia, the liver
quickly switched from net production to net uptake
(1st-pass), as indicated by negative NHGA. The addition
of exenatide further increased net hepatic uptake of
portally infused glucose, reducing the amount of portal
exogenous glucose entering the systemic circulation. A
higher portal glucose infusion associated with exenatide
treatment led to a slight increase in hepatic glucose load
by 12% compared with the saline control, but it cannot
completely account for the 83 and 45% increase in
NHGA (net uptake) in studies 1 and 2. Importantly, it is
known that impaired suppression of endogenous glu-
cose production and reduced splanchnic glucose uptake
contribute to postprandial hyperglycemia in type 2
diabetic patients (35,36). The present work suggests
that exenatide can increase uptake of exogenous glu-
cose by the liver, limiting the appearance of exogenous
glucose in the system similarly to its known action to
reduce gastric emptying. The observation that exenatide
signiﬁcantly increased net hepatic glucose uptake (1st-
pass) in the liver facing elevated insulin and glucose
levels suggests that it might promote the conversion of
glucose into glycogen at the cellular level. A few in vitro
studies indicate that GLP-1 and exendin-4 exert a stim-
ulatory effect on glycogen synthase a but an inhibitory
effect on glycogen phosphorylase a in the liver and
muscle (37,38). Glucokinase appears to be another good
candidate because it is pivotal for hepatic glycogen
synthesis and because its cytoplasmic activity has been
shown to be regulated by insulin and glucose (39–42).
In summary, the present study was designed to under-
stand the mechanisms of action of the glucose-lowering
effect of exenatide in postprandial conditions. Our results
reveal a novel mechanism: Exenatide potentiates insulin-
mediated glucose disposal, acting as an insulin sensitizer.
Speciﬁcally, exenatide enhances whole-body glucose dis-
posal, increasing the Rd while it also increases the uptake
of portally delivered exogenous glucose by the liver,
decreasing the Ra. Although a direct enhancement of
insulin sensitivity by exenatide is conﬁned to healthy
animals in the present study, it appears that such a
mechanism might as well exist in insulin-resistant condi-
tions. There is evidence that GLP-1 and exendin-4 enhance
insulin action, acutely or chronically, in obese, insulin-
resistant, or type 2 diabetic humans and animals
(28,29,31,43–46). Nonetheless, whether exenatide is capa-
ble of reversing or improving insulin sensitivity in insulin-
resistant conditions, e.g., a diet-induced obese dog model
manifesting central obesity and deterioration of insulin
action in the liver and periphery (36,47,48), should be
further studied.
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